Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures

Huei Chi Wen; Tali Czarnowicki; Shinji Noda; Kunal Malik; Ana B. Pavel; Saeko Nakajima; Tetsuya Honda; Jung U. Shin; Hemin Lee; Margaret Chou; Yeriel Estrada; Xiuzhong Zheng; Hui Xu; James G. Krueger; Kwang Hoon Lee; Kenji Kabashima; Emma Guttman-Yassky

doi:10.1016/j.jaci.2018.02.047

Serum from Asian patients with atopic dermatitis is characterized by T_H2/T_H22 activation, which is highly correlated with nonlesional skin measures

Huei Chi Wen, Tali Czarnowicki, Shinji Noda, Kunal Malik, Ana B. Pavel, Saeko Nakajima, Tetsuya Honda, Jung U. Shin, Hemin Lee, Margaret Chou, Yeriel Estrada, Xiuzhong Zheng, Hui Xu, James G. Krueger, Kwang Hoon Lee, Kenji Kabashima, Emma Guttman-Yassky

Department of Dermatology

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Original language	English
Pages (from-to)	324-328.e11
Journal	Journal of Allergy and Clinical Immunology
Volume	142
Issue number	1
DOIs	https://doi.org/10.1016/j.jaci.2018.02.047
Publication status	Published - 2018 Jul

Bibliographical note

Funding Information:
Supported by a research grant (to E.G.-Y.) from Leo Pharma.

Funding Information:
Disclosure of potential conflict of interest: S. Nakajima received grants from Sanofi Japan, the Kanae Foundation for the Promotion of Medical Science, and GlaxoSmithKline Japan for other works. T. Honda's institution received grants from Mitsubishi Tanabe Pharma, Sanofi Japan Group, AbbVie GK, Lydia O'Leary Memorial Pias Dermatological Foundation, ROHTO Pharmaceutical, Shiseido, Novartis international AG, and Kao, and the institution received payment for lectures from Novartis international AG, AbbVie GK, Sanofi Japan Group, Mitsubishi Tanabe Pharma, Janssen Pharma, Kyowa Hakko Kirin, and Torii Pharmaceutical. J. G. Krueger's institution received fees from Novartis, Pfizer, Amgen, Boehringer, Innovaderm, BMS, Janssen, AbbVie, Paraxel, Leo Pharma, Vitae, Acros, Kineta, Regeneron, Novan, BiogenMA, Sienna, UCB, and Allergan and personally received money from Novartis, Pfizer, Amgen, Lilly, Boehringer, BiogenIdec, Janssen, AbbVie, Leo Pharma, ESCALIER, Acros, Roche, Valeant, Allergan, Aurigene, and Asana. E. Guttman-Yassky received board membership from Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, Leo Pharma, AnaptysBio, Celsus, Dermira, Galderma, Novartis, Pfizer, Vitae, Glenmark, AbbVie, and Asana Biosciences and consultancy fees from Regeneron, Sanofi Aventis, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Leo Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe, Eli Lilly, Glenmark, and Asana Biosciences; her institution received grants from Regeneron, Celgene, BMS, Janssen, Dermira, Leo Pharma, Merck, Novartis, and UCB for other works. The rest of the authors declare that they have no relevant conflicts of interest. Letter to the Editor

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2018.02.047

Cite this

Wen, H. C., Czarnowicki, T., Noda, S., Malik, K., Pavel, A. B., Nakajima, S., Honda, T., Shin, J. U., Lee, H., Chou, M., Estrada, Y., Zheng, X., Xu, H., Krueger, J. G., Lee, K. H., Kabashima, K., & Guttman-Yassky, E. (2018). Serum from Asian patients with atopic dermatitis is characterized by T_H2/T_H22 activation, which is highly correlated with nonlesional skin measures. Journal of Allergy and Clinical Immunology, 142(1), 324-328.e11. https://doi.org/10.1016/j.jaci.2018.02.047

Wen, Huei Chi ; Czarnowicki, Tali ; Noda, Shinji ; Malik, Kunal ; Pavel, Ana B. ; Nakajima, Saeko ; Honda, Tetsuya ; Shin, Jung U. ; Lee, Hemin ; Chou, Margaret ; Estrada, Yeriel ; Zheng, Xiuzhong ; Xu, Hui ; Krueger, James G. ; Lee, Kwang Hoon ; Kabashima, Kenji ; Guttman-Yassky, Emma. / Serum from Asian patients with atopic dermatitis is characterized by T_H2/T_H22 activation, which is highly correlated with nonlesional skin measures. In: Journal of Allergy and Clinical Immunology. 2018 ; Vol. 142, No. 1. pp. 324-328.e11.

@article{2044a4d79f5e4de4a079ff1b7662c89b,

title = "Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures",

author = "Wen, {Huei Chi} and Tali Czarnowicki and Shinji Noda and Kunal Malik and Pavel, {Ana B.} and Saeko Nakajima and Tetsuya Honda and Shin, {Jung U.} and Hemin Lee and Margaret Chou and Yeriel Estrada and Xiuzhong Zheng and Hui Xu and Krueger, {James G.} and Lee, {Kwang Hoon} and Kenji Kabashima and Emma Guttman-Yassky",

note = "Funding Information: Supported by a research grant (to E.G.-Y.) from Leo Pharma. Funding Information: Disclosure of potential conflict of interest: S. Nakajima received grants from Sanofi Japan, the Kanae Foundation for the Promotion of Medical Science, and GlaxoSmithKline Japan for other works. T. Honda's institution received grants from Mitsubishi Tanabe Pharma, Sanofi Japan Group, AbbVie GK, Lydia O'Leary Memorial Pias Dermatological Foundation, ROHTO Pharmaceutical, Shiseido, Novartis international AG, and Kao, and the institution received payment for lectures from Novartis international AG, AbbVie GK, Sanofi Japan Group, Mitsubishi Tanabe Pharma, Janssen Pharma, Kyowa Hakko Kirin, and Torii Pharmaceutical. J. G. Krueger's institution received fees from Novartis, Pfizer, Amgen, Boehringer, Innovaderm, BMS, Janssen, AbbVie, Paraxel, Leo Pharma, Vitae, Acros, Kineta, Regeneron, Novan, BiogenMA, Sienna, UCB, and Allergan and personally received money from Novartis, Pfizer, Amgen, Lilly, Boehringer, BiogenIdec, Janssen, AbbVie, Leo Pharma, ESCALIER, Acros, Roche, Valeant, Allergan, Aurigene, and Asana. E. Guttman-Yassky received board membership from Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, Leo Pharma, AnaptysBio, Celsus, Dermira, Galderma, Novartis, Pfizer, Vitae, Glenmark, AbbVie, and Asana Biosciences and consultancy fees from Regeneron, Sanofi Aventis, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Leo Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe, Eli Lilly, Glenmark, and Asana Biosciences; her institution received grants from Regeneron, Celgene, BMS, Janssen, Dermira, Leo Pharma, Merck, Novartis, and UCB for other works. The rest of the authors declare that they have no relevant conflicts of interest. Letter to the Editor ",

year = "2018",

month = jul,

doi = "10.1016/j.jaci.2018.02.047",

language = "English",

volume = "142",

pages = "324--328.e11",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "1",

}

Wen, HC, Czarnowicki, T, Noda, S, Malik, K, Pavel, AB, Nakajima, S, Honda, T, Shin, JU, Lee, H, Chou, M, Estrada, Y, Zheng, X, Xu, H, Krueger, JG, Lee, KH, Kabashima, K & Guttman-Yassky, E 2018, 'Serum from Asian patients with atopic dermatitis is characterized by T_H2/T_H22 activation, which is highly correlated with nonlesional skin measures', Journal of Allergy and Clinical Immunology, vol. 142, no. 1, pp. 324-328.e11. https://doi.org/10.1016/j.jaci.2018.02.047

Serum from Asian patients with atopic dermatitis is characterized by T_H2/T_H22 activation, which is highly correlated with nonlesional skin measures. / Wen, Huei Chi; Czarnowicki, Tali; Noda, Shinji; Malik, Kunal; Pavel, Ana B.; Nakajima, Saeko; Honda, Tetsuya; Shin, Jung U.; Lee, Hemin; Chou, Margaret; Estrada, Yeriel; Zheng, Xiuzhong; Xu, Hui; Krueger, James G.; Lee, Kwang Hoon; Kabashima, Kenji; Guttman-Yassky, Emma.

In: Journal of Allergy and Clinical Immunology, Vol. 142, No. 1, 07.2018, p. 324-328.e11.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures

AU - Wen, Huei Chi

AU - Czarnowicki, Tali

AU - Noda, Shinji

AU - Malik, Kunal

AU - Pavel, Ana B.

AU - Nakajima, Saeko

AU - Honda, Tetsuya

AU - Shin, Jung U.

AU - Lee, Hemin

AU - Chou, Margaret

AU - Estrada, Yeriel

AU - Zheng, Xiuzhong

AU - Xu, Hui

AU - Krueger, James G.

AU - Lee, Kwang Hoon

AU - Kabashima, Kenji

AU - Guttman-Yassky, Emma

N1 - Funding Information: Supported by a research grant (to E.G.-Y.) from Leo Pharma. Funding Information: Disclosure of potential conflict of interest: S. Nakajima received grants from Sanofi Japan, the Kanae Foundation for the Promotion of Medical Science, and GlaxoSmithKline Japan for other works. T. Honda's institution received grants from Mitsubishi Tanabe Pharma, Sanofi Japan Group, AbbVie GK, Lydia O'Leary Memorial Pias Dermatological Foundation, ROHTO Pharmaceutical, Shiseido, Novartis international AG, and Kao, and the institution received payment for lectures from Novartis international AG, AbbVie GK, Sanofi Japan Group, Mitsubishi Tanabe Pharma, Janssen Pharma, Kyowa Hakko Kirin, and Torii Pharmaceutical. J. G. Krueger's institution received fees from Novartis, Pfizer, Amgen, Boehringer, Innovaderm, BMS, Janssen, AbbVie, Paraxel, Leo Pharma, Vitae, Acros, Kineta, Regeneron, Novan, BiogenMA, Sienna, UCB, and Allergan and personally received money from Novartis, Pfizer, Amgen, Lilly, Boehringer, BiogenIdec, Janssen, AbbVie, Leo Pharma, ESCALIER, Acros, Roche, Valeant, Allergan, Aurigene, and Asana. E. Guttman-Yassky received board membership from Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, Leo Pharma, AnaptysBio, Celsus, Dermira, Galderma, Novartis, Pfizer, Vitae, Glenmark, AbbVie, and Asana Biosciences and consultancy fees from Regeneron, Sanofi Aventis, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Leo Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe, Eli Lilly, Glenmark, and Asana Biosciences; her institution received grants from Regeneron, Celgene, BMS, Janssen, Dermira, Leo Pharma, Merck, Novartis, and UCB for other works. The rest of the authors declare that they have no relevant conflicts of interest. Letter to the Editor

PY - 2018/7

Y1 - 2018/7

UR - http://www.scopus.com/inward/record.url?scp=85046133968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046133968&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2018.02.047

DO - 10.1016/j.jaci.2018.02.047

M3 - Article

C2 - 29653116

AN - SCOPUS:85046133968

VL - 142

SP - 324-328.e11

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -